SEATTLE, May 29 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) today announced presentations of interest on lung cancer and on its development candidate XYOTAX(TM) (paclitaxel poliglumex) at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1-5, 2007, in Chicago.
Date Time Poster # Title (Abstract#) Sat., June 2 8:00 AM 23 Toxicity and survival by sex in poster (7549) patients with advanced non-small Noon: cell lung carcinoma (NSCLC) on discussion modern Southwest Oncology Group (SWOG) trials Sun., June 3 8:00 AM T7 Single-agent compared to combination poster (7637) first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2. Sun., June 3 8:00 AM Z4 Serum free estradiol (E2) levels are poster (7683) prognostic in men with chemotherapy-naive advanced non-small cell lung cancer (NSCLC)and performance status (PS)2. Publication 15130 Paclitaxel poliglumex (PPX), only cisplatin, and concurrent radiation for esophageal and gastric cancer: a phase I study. Publication 18036 Serum cathepsin B levels are only prognostic in chemotherapy-naive advanced NSCLC PS2 patients; analysis of results from STELLAR 3 and 4. Publication 18172 Medical research utilization (MRU) only and costs associated with XYOTAX(TM) (CT-2103, paclitaxel poliglumex, PPX) compared to gemcitabine or vinorelbine in the treatment of non-small cell lung cancer patients.
For more information about the ASCO annual meeting, please refer to the conference Web site at http://www.asco.org/.
In addition, the annual meeting of National Lung Cancer Partnership, scheduled for Friday, 1 from 8:00 AM to Noon, will include a scientific discussion titled “Epigenetics and Sex Differences in Lung Cancer.” For more information, please refer to their Web site at http://www.nationallungcancerpartnership.org.
About XYOTAX
XYOTAX(TM) (paclitaxel poliglumex) is a biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue’s exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that XYOTAX is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that XYOTAX metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.
Media Contact: Dan Eramian T: 206.272.4343 C: 206.854.1200 Susan Callahan T: 206.272.4472 F: 206.272.4434 E: media@ctiseattle.comhttp://www.cticseattle.com/media.htm Investors Contact: Leah Grant T: 206.282.7100 F: 206.272.4434 E: invest@ctiseattle.comhttp://www.cticseattle.com/investors.htm Medical Information Contact: T: 800.715.0944 E: info@askarm.com
Cell Therapeutics, Inc.
CONTACT: media, Dan Eramian, +1-206-272-4343, cell +1-206-854-1200, orSusan Callahan, +1-206-272-4472, fax +1-206-272-4434, media@ctiseattle.com,or, investors, Leah Grant, +1-206-282-7100, fax +1-206-272-4434,invest@ctiseattle.com, or, for medical information, 1-800-715-0944,info@askarm.com, all of Cell Therapeutics, Inc.
